Related Experiment Video

Updated: May 15, 2026

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

Targeting c-FLICE-like inhibitory protein (CFLAR) in cancer

Simone Fulda1

  • 1Goethe-University Frankfurt, Institute for Experimental Cancer Research in Pediatrics, Komturstr. 3a, 60528 Frankfurt, Germany. simone.fulda@kgu.de

Expert Opinion on Therapeutic Targets
|December 21, 2012
PubMed
Abstract

Insights

Evasion of apoptosis, a hallmark of cancer, is linked to antiapoptotic proteins like c-FLICE-like inhibitory protein (c-FLIP). Understanding c-FLIP regulation is key to developing new cancer therapies targeting cell death pathways.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Death Research

Background:

  • Evasion of apoptosis is a hallmark of human cancers.
  • Aberrant expression of antiapoptotic proteins, such as c-FLICE-like inhibitory protein (c-FLIP), contributes to cancer development.
  • c-FLIP inhibits apoptosis signaling and regulates other cell death pathways.

Purpose of the Study:

  • To investigate the regulation of c-FLIP expression and activity in human cancers.
  • To explore c-FLIP as a potential therapeutic target for cancer treatment.

Main Methods:

  • Analysis of transcriptional and posttranscriptional regulation of c-FLIP.
  • Study of c-FLIP's role in modulating cell death signaling.
  • Examination of c-FLIP expression in various cancers.

Main Results:

  • c-FLIP is a short-lived protein with rapid turnover.
  • Regulation of c-FLIP expression offers a versatile approach to modulate cell death pathways.
  • Aberrant c-FLIP expression is observed in various cancers.

Conclusions:

  • Insights into c-FLIP regulation are crucial for developing novel cancer therapies.
  • Targeting c-FLIP expression presents a promising strategy for cancer intervention.
  • Further research into molecular events regulating c-FLIP will advance cancer treatment.

More Related Videos

SorLA and CLC:CLF-1-dependent Downregulation of CNTFRα as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry10:16

SorLA and CLC:CLF-1-dependent Downregulation of CNTFRα as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry

Published on: January 6, 2017

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 406:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However, invadopodia can...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...